Our top pick for
Building a portfolio
Enlivex Therapeutics Ltd is a biotechnology business based in the US. Enlivex Therapeutics shares (ENLV) are listed on the NASDAQ and all prices are listed in US Dollars. Enlivex Therapeutics employs 36 staff and has a market cap (total outstanding shares value) of USD$245.3 million.
|52-week range||USD$3.65 - USD$29.4|
|50-day moving average||USD$15.748|
|200-day moving average||USD$11.0899|
|Wall St. target price||USD$33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.419|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-21.22%|
|Return on equity TTM||-41.75%|
|Market capitalisation||USD$245.3 million|
TTM: trailing 12 months
There are currently 95,191 Enlivex Therapeutics shares held short by investors – that's known as Enlivex Therapeutics's "short interest". This figure is 64.5% up from 57,868 last month.
There are a few different ways that this level of interest in shorting Enlivex Therapeutics shares can be evaluated.
Enlivex Therapeutics's "short interest ratio" (SIR) is the quantity of Enlivex Therapeutics shares currently shorted divided by the average quantity of Enlivex Therapeutics shares traded daily (recently around 951910). Enlivex Therapeutics's SIR currently stands at 0.1. In other words for every 100,000 Enlivex Therapeutics shares traded daily on the market, roughly 100 shares are currently held short.
However Enlivex Therapeutics's short interest can also be evaluated against the total number of Enlivex Therapeutics shares, or, against the total number of tradable Enlivex Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Enlivex Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Enlivex Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.007% of the tradable shares (for every 100,000 tradable Enlivex Therapeutics shares, roughly 7 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Enlivex Therapeutics.
Find out more about how you can short Enlivex Therapeutics stock.
We're not expecting Enlivex Therapeutics to pay a dividend over the next 12 months.
Enlivex Therapeutics's shares were split on a 1:8 basis on 5 March 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Enlivex Therapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Enlivex Therapeutics shares which in turn could have impacted Enlivex Therapeutics's share price.
Enlivex Therapeutics Ltd operates as a clinical stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and various others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.